Morbidity and Mortality Weekly Report, December 14, 1984 / 33(49);685-7
Recent studies have provided important additional assurances concerning the safety of hepatitis B (HB) vaccine. The vaccine currently licensed in the United States is produced from pooled plasma of hepatitis B surface antigen-positive individuals, some of whom are also in high-risk groups for acquired immunodeficiency syndrome (AIDS).
Morbidity and Mortality Weekly Report, November 30, 1984 / 33(47);661-4
As of November 26, 1984, physicians and health departments in the United States had reported 6,993 patients meeting the surveillance definition for acquired immunodeficiency syndrome (1,2). Over 86% of the adult AIDS patients and 82% of the pediatric patients have been reported since January 1983 (Figure 1).
Morbidity and Mortality Weekly Report, November 23, 1984 / 33(46);659-60
December 10, 1984, is the deadline for receipt of abstracts to be considered for presentation at the International Conference on Acquired Immunodeficiency Syndrome (AIDS), which will be held in Atlanta, Georgia, at the Georgia World Congress Center on April 14-17, 1985.
Morbidity and Mortality Weekly Report, November 02, 1984 / 33(43);607-9
Ten countries provide the World Health Organization (WHO) Collaborating Centre on Acquired Immunodeficiency Syndrome (AIDS), Paris, France, with regular data, making follow-up and study of the AIDS situation possible in Europe (1); these countries are: Denmark, France, the Federal Republic of Germany, Greece, Italy, the Netherlands, Spain, Sweden, Switzerland, and the United Kingdom.
Morbidity and Mortality Weekly Report, October 26, 1984 / 33(42);589-91
Reports of hemophilia-associated acquired immunodeficiency syndrome (AIDS) in the United States were first published in July 1982 (1). Since then, the number of U.S. patients with underlying coagulation disorders who develop AIDS has increased each year.
Morbidity and Mortality Weekly Report, August 03, 1984 / 33(30);444
An International Conference on Acquired Immunodeficiency Syndrome (AIDS) will be held April 15-17, 1985, at the World Congress Center, Atlanta, Georgia, sponsored by CDC; the National Institutes of Health; the Food and Drug Administration; the Alcohol, Drug Abuse, and Mental Health Administration; the Health Resources and Services Administration; and the World Health Organization.
Morbidity and Mortality Weekly Report, August 03, 1984 / 33(30);442-3
Evidence from two investigations indicates that the retrovirus etiologically linked to acquired immunodeficiency syndrome (AIDS) may infect chimpanzees (Pan troglodytes). In the first study, investigators from CDC and Emory University's Yerkes Regional Primate Research Center, Atlanta, Georgia, inoculated two chimpanzees with lymphadenopathy-associated virus (LAV)
Morbidity and Mortality Weekly Report, July 13, 1984 / 33(27);377-9
Evidence implicates a retrovirus as the etiologic agent of acquired immunodeficiency syndrome (AIDS). Two prototype isolates have been described. One was isolated from the lymph node cells of a homosexual man with unexplained generalized lymphadenopathy, a syndrome associated with AIDS, and was termed lymphadenopathy-associated virus (LAV).
Morbidity and Mortality Weekly Report, June 22, 1984 / 33(24);337-9
As of June 18, 1984, physicians and health departments in the United States had reported 4,918 patients meeting the surveillance definition for acquired immunodeficiency syndrome (1,2). Over 70% of the adult AIDS patients and nearly 80% of the pediatric patients have been reported since January 1983.
Morbidity and Mortality Weekly Report, June 01, 1984 / 33(21);295-7
The rates of rectal and pharyngeal gonorrhea for New York City males aged 15-44 years* has declined from 129 per 100,000 males in that age group in 1980 to 74/100,000 in 1983--the lowest level in the past 7 years.
Morbidity and Mortality Weekly Report, June 01, 1984 / 33(21);285-90
The following statement supplements and updates certain sections of two previous statements on hepatitis B virus prophylaxis (MMWR 1981;30:423-35 and MMWR 1982;31:317-28 {1,2}). Those statements should be consulted regarding preexposure use of hepatitis B vaccine and prophylaxis of hepatitis A.
Morbidity and Mortality Weekly Report, May 18, 1984 / 33(19);270
A U.S.-manufactured preparation of pentamidine isethionate has undergone satisfactory completion of chemical and biologic tests, and CDC is now able to include this preparation in its claimed investigational exemption for a new drug for treatment of Pneumocystis carinii pneumonia.
Morbidity and Mortality Weekly Report, May 04, 1984 / 33(17);225-6
Pentamidine is used to treat patients with Pneumocystis carinii pneumonia (PCP) who have failed to respond or who have had adverse reactions to trimethoprim/sulfamethoxazole. Because of the unavailability of an approved product and the infrequent demand for the drug in the United States, CDC has supplied pentamidine through its Parasitic Disease Drug Service as an Investigational New Drug.
Morbidity and Mortality Weekly Report, April 06, 1984 / 33(13);181-2
In August 1983, CDC initiated prospective surveillance of health-care workers with documented parenteral or mucous-membrane exposures to potentially infectious body fluids from patients with definite or suspected acquired immunodeficiency syndrome (AIDS).
Morbidity and Mortality Weekly Report, March 09, 1984 / 33(9);117-9
In November 1982, 21 patients with acquired immunodeficiency syndrome (AIDS) and severe, protracted diarrhea caused by cryptosporidiosis were reported; the report concluded that no effective treatment for cryptosporidiosis was known at that time (1). Since then, 91 additional AIDS patients with chronic cryptosporidiosis have been reported to CDC.
Morbidity and Mortality Weekly Report, February 17, 1984 / 33(6);65-7
During November 1983, three patients at one New York City hospital who had the acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia (PCP) developed severe neutropenia while being treated with pentamidine isethionate.
Morbidity and Mortality Weekly Report, January 06, 1984 / 32(52);688-91
As of December 19, 1983, physicians and health departments in the United States have reported a total of 3,000 patients who meet the surveillance definition for acquired immunodeficiency syndrome (AIDS) (1). Of these patients, 51% were reported to have had Pneumocystis carinii pneumonia (PCP) without Kaposi's sarcoma (KS); 26%, KS without PCP; 7%, both KS and PCP; and 16%, opportunistic infections without either KS or PCP.
This information is designed to support, not replace, the relationship that exists between you and your doctor.